Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005
Wood D, Kosa K, Brown D, Ehrlich OG, Higgins PDR, Heller C. Preferences of adult patients with inflammatory bowel disease for attributes of clinical trials: evidence from a choice-based conjoint analysis. Crohns Colitis 360. 2020 Jan;2(1). doi: 10.1093/crocol/otz048
Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Hershey N, Cann CI, Rothman KJ. Reply: overcoming hurdles to epidemiologic research. E & HR. 1985 Mar;7(2):9. doi: 10.2307/3564146
Cann CI, Rothman KJ. IRBs and epidemiologic research: how inappropriate restrictions hamper studies. E & HR. 1984 Jul;6(4):5-7. doi: 10.2307/3564590